Skip to Content
Search Menu

WCLC 2023 – NSCLC: New Data on Perioperative Immunotherapy Treatment 

Can perioperative treatment with Imfinzi in combination with chemotherapy improve the pathological complete response (pCR) and increase event-free survival (EFS) in patients with resectable NSCLC with a positive PD-L1 status?

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Relateret indhold

Katharina Leuchte

ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

/ Katharina Leuchte
ESMO25Lung cancer Play the Video 05:43
Pasi Jänne

New Class of Medicines Emerge as Potential Therapies in MTAP-Deleted NSCLC

/ Pasi Jänne
Lung cancerNSCLCWCLC25 Play the Video 03:28

Lung Cancer Insights: What’s New in the Field

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancerLung cancer-highlights
Michael Stenger

WCLC 2025: Lung Cancer Screening and Early Results from the Danish PLUS Trial

/ Michael Stenger
Lung cancerWCLC25 Play the Video 12:24

New Data Support Osimertinib as a Backbone Treatment for EGFRm Advanced NSCLC

/ Jan Andreasen
Lung cancerNSCLCWCLC25

Amivantamab + Lazertinib in EGFR-Mutated Advanced NSCLC: PALOMA-2 Update

/ Jan Andreasen
Lung cancerNSCLCWCLC25

First-Line NSCLC Without Driver Mutations: Practice, Gaps, and Costs

/ Ronny Öhman / Jan Andreasen
Lung cancerNSCLC
Maria Silvoniemi

Clinical Dilemmas in the Management of NSCLC Without Driver Mutations

/ Maria Silvoniemi
Lung cancerNSCLC Play the Video 10:41
Luis Paz-Ares

ASCO 2025: Lurbinectedin–Atezolizumab Improves Survival in SCLC

/ Luis Paz-Ares
ASCO25Lung cancer Play the Video 18:02
Back to top